Moreover, we strongly recommend that serum tumor marker levels should be evaluated in patients who are highly suspected of having NSCLC or initially diagnosed with NSCLC, especially SCCA, CYFRA21-1. This evidence concerns the gene SERPINB3 and non-small cell lung carcinoma.